ÇERKEZKÖY 1 MANUFACTURING SITE
DEVA Holding Çerkezköy-I Manufacturing Facility, located approximately at a 110 km distance to Istanbul, is founded on an area of 52,000 m2 in Çerkezköy Organized Industrial Zone with closed facilities of 36,000 m2. The facility comprises of modern buildings where liquids/semi-solids and solids, cephalosporin, penicillin, hormone-containing products, inhaled products, sterile liquid ampoules and vials, and soft gel capsules are manufactured.
 

In the production facility, a total of 153 million units were manufactured in 2019 compared to 152 million units in 2020.

Liquid / Semi Solid and Solids Manufacturing Area

In the liquid and semi-solid area, syrup-drop and spray, creams and gels, suppository and pessary-form products are manufactured using the state-of-art technology.

In the unit, in which a total of 25 million units were manufactured in 2019, a total of 25 million units were produced in 2020, including 18 million syrup drops and sprays, 7 million pomade cream-gels and suppository ovules



In the solids unit, tablets and film coated tablets, capsules and powder suspensions-form drugs are manufactured using the state-of-art technology.

In this unit, in which 58.9 million units of product were manufactured in 2019, a total of 58.4 million units were manufactured in 2020, of which 56.2 million units were tablets/soft gel capsules, and 2.2 million units were suspensions.



Cephalosporin Manufacturing Area (Betalactam I)

In the cephalosporin unit, where 27 million units were manufactured in 2019, a total of 26.1 million units of pharmaceutical products were manufactured in 2020; 23 million units of injectable sterile powder vials, 700 thousand units of oral suspensions, and 2.4 million units of coated tablets and capsules.


Penicillin Manufacturing Area (Betalactam II)

Whereas, in the penicillin unit, 18.8 million units were manufactured in 2019, a total of 19.3 million units of pharmaceutical products were manufactured in 2020; 7.5 million units of injectable sterile powder vials, 3.9 million units of oral suspensions, and 7.9 million units of filmcoated tablets.

 

There has been a 3% increase in the penicillin unit’s production in 2020 compared to 2019.



Hormone Products Manufacturing Area

Whereas, in the hormone products unit, 18.6 million units of products were manufactured in 2019; approximately 19.4 million units or product were manufactured in 2020; 3.6 million units of creams/pomades, 3.3 million units of solid tablets and film-coated tablets, and 12.5 million units of sterile ampoules, vials, and drops.

There was a 4% increase in hormone production in 2020 compared to 2019.



Inhaled Products Manufacturing Area

3.5 million units of MDI and DPI were manufactured in 2019 compared to 3 million units in 2020.

 

Sterile Liquid Ampoule and Vial and Soft Gel Capsule Products Manufacturing Area

In the Sterile Liquid Ampoule and Vial unit, 1.1 million units of sterile vials were manufactured in 2019, while 1.6 million units of vials were manufactured in 2020.

In 2020, there was a 45% increase in sterile liquid production compared to 2019.